載入...
The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control
BACKGROUND: iGlarLixi is an injectable combination of long acting insulin glargine (iGlar) and glucagon-like peptide 1 receptor agonist lixisenatide in a fixed ratio, which was proven safe and effective for the treatment of type 2 diabetes. Lixisenatide and iGlar act differently on fasting and postp...
Na minha lista:
| 發表在: | J Diabetes Sci Technol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8256059/ https://ncbi.nlm.nih.gov/pubmed/31810389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296819891170 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|